NLP SNP

Report for Mutation M235T

Developed by Shray Alag, 2020.

SNP Clinical Trial Gene

There are 4 clinical trials

Clinical Trials

1 Antihypertensive Drug/Gene Interactions and CV Events

To investigate drug-gene interactions on the incidence of non-fatal myocardial infarction and stroke for hypertensive patients.

NCT00005332 Cardiovascular Diseases Heart Diseases Myocardial Infarction Hypertension Cerebrovascular Accident

MeSH:Stroke Heart Diseases Myocardial Infarction Infarction Cardiovascular Diseases

HPO:Abnormality of the cardiovascular system Myocardial infarction Stroke

The study also assesses other potential gene-drug interactions with the G-protein beta-3 subunit (GB3) polymorphism, B2AR-16 polymorphism, the amiloride-sensitive epithelial sodium channel, and the angiotensinogen Met235Thr polymorphism. --- Met235Thr ---

2 Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria

Aim: To evaluate the renoprotective effect as reflected by short-term changes in albuminuria of ultra high doses of irbesartan in Type 2 diabetic patients with microalbuminuria Design: A double-masked randomized cross-over trial including 60 hypertensive Type 2 diabetic patients with microalbuminuria on ongoing antihypertensive medication. At inclusion, previous antihypertensive treatment will be discontinued and replaced with bendroflumethiazide 5 mg o.d. for the entire study. Following two months wash-out (baseline), patients will be treated randomly with irbesartan 300, 600 and 900 mg o.d., each dose for two months. End-points evaluated at the end of each study period include urinary albumin excretion rate (UAE, mean of three 24-hrs collections), 24-hrs blood pressure (ABP); and GFR (51Cr-EDTA).

NCT00320879 Type 2 Diabetes Microalbuminuria Drug: irbesartan

MeSH:Albuminuria

HPO:Albuminuria

Initially we will evaluate the influence of the ACE/ID- , Angiotensin II type I receptor (A1166C) - and the angiotensinogen (M235T) polymorphisms. --- A1166C --- --- M235T ---

Primary Outcomes

Measure: urinary albumin excretion rate

Secondary Outcomes

Measure: ambulatory blood pressure

Measure: glomerular filtration rate

Measure: serum potassium

Measure: serum creatinine

Measure: lipids

Measure: renin

Measure: aldosterone

Measure: NT-proBNP

Measure: markers of endothelial function

Measure: markers of inflammation

Measure: genotypes with possible implications for the risk of cardiovascular disease

3 Observational Study of the Polymorphisms of the Renin-angiotensin-aldosterone System and Their Relation to Resistant Systemic Arterial Hypertension and Adverse Cardiovascular Events

Renin-angiotensin-aldosterone system (RAAS) polymorphisms influence 24h arterial pressure fluctuation. Resistant systemic arterial hypertension (RSAH) has an increased risk of end organ damage and unfavourable prognosis, whereas pseudo-RSAH usually respond favourably to drug therapy. To prospectively investigate, in subjects with RSAH in a tropical South American city: 1) Adverse cardiovascular events defined as fatal and non-fatal stroke or acute myocardial infarction (AMI); and 2) the association of RAAS polymorphisms and adverse cardiovascular events in this population. Study population: 212 hypertensives recruited from primary care assistance (time since first diagnosis of hypertension: 16.5±8.1 years) and without appropriate pressure control, between 2001 and 2006, corresponding to 0.48% of all hypertensives under care (18 new cases/year), 57±10 years old, 66% females. Under drug treatment schedule: three or more drugs including a diuretic. Ninety two randomly selected hypertensives basis had renin-angiotensin-aldosterone system genetic profile determined. Genetic assessment was carried out using a polymerase chain reaction assay amplification technique. The following single nucleotide polymorphisms were analyzed: renin (G1051A), angiotensinogen (M235T), angiotensin converting enzyme-ACE (I/D), angiotensin II type 1 receptor (A1166C), aldosterone synthase (C344T) and mineralocorticoid receptor (G3514C).

NCT01173029 Systemic Arterial Hypertension Hypertension Resistant to Conventional Therapy Myocardial Infarction Stroke Drug: Anti-hypertensive drug treatment

MeSH:Hypertension Myocardial Infarction Coronary Vasospasm Infarction

HPO:Hypertension Myocardial infarction

The following single nucleotide polymorphisms were analyzed: renin (G1051A), angiotensinogen (M235T), angiotensin converting enzyme-ACE (I/D), angiotensin II type 1 receptor (A1166C), aldosterone synthase (C344T) and mineralocorticoid receptor (G3514C). --- G1051A --- --- M235T ---

Primary Outcomes

Description: Evidence of clinically definite stroke (focal neurological deficits persisting for more than 24 hours) confirmed or not by non-investigational computerized tomography. Death was considered to be related to the event if occurring up to 30 days after the acute event. Assessment twice an year by active and direct contact to patients or relatives and review of medical records.

Measure: Strokes, Either Fatal or Nonfatal

Time: up to 10 years

Secondary Outcomes

Description: Evidence of clinically definite stroke (focal neurological deficits persisting for more than 24 hours) confirmed or not by non-investigational computerized tomography. Evidence of clinically definite acute myocardial infarction (prolonged > 20min chest pain, not relieved by sublingual nitrate, ST-T segment deviation on 12-lead surface ECG, elevation of plasma troponin >0.2 ng/dL 6h following chest pain episode). Death was considered to be related to the event if occurring up to 30 days after the acute event. Assessment twice an year by active and direct contact to patients or relatives and review of medical records.

Measure: Composite of Acute Myocardial Infarctions and/or Strokes Either Fatal or Nonfatal

Time: up to 10 years

4 Study of Polymorphisms of Renin Angiotensin Aldosteron Systemv(RAAS) and Matrice Metallo Protesase (MMPs) in Acute Heart Failure (AHF)

this study aim to investigate the: - association of RAAS polymorphisms and AHF - association of MMP 3 and 12 polymorphisms and AHF

NCT02170961 Acute Heart Failure

MeSH:Heart Failure

HPO:Congestive heart failure Left ventricular dysfunction Right ventricular failure

To date, few published studies have examined the association between the polymorphism AGT M235T * and cardiac dysfunction; and available results are contradictory. --- M235T ---

Primary Outcomes

Description: the association between RAAS genes polymorphisms and mortality at one year average

Measure: mortality RAAS

Time: one year

Secondary Outcomes

Description: the association between the diagnosis of AHF (based on clinical, BNP, and echocardiographic finds) and the RAAS genes polymorphism is studied at patient admission for acute dyspnea.

Measure: association between RAAS polymorphism and AHF

Time: at admission (an average of 1 day)

Description: the association between the diagnosis of AHF (based on clinical, BNP, and echocardiographic finds) and the MMP genes polymorphism is studied at patient admission for acute dyspnea.

Measure: association between MMP polymorphism and AHF

Time: at admission (average of 1 day)